Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Javier Crespo

Profesor Titular

University Name

Spain

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

40%

Internal Medicine

40%

Liver Fibrosis

80%

Fatty Liver

40%

Metabolic Syndrome

30%

Enzyme Replacement Therapy

30%

Antiretroviral Therapy

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

A novel Hepatitis c micrOelimination program in Non imprisonEd SenTenced with alternative measures. The HONEST project. HCV CHIME program: Conquering Hepatitis vIa Micro-Elimination.

Open Date: 2019-01-01

Close Date: 2020-12-01

Grant: Close

Glutamine Metabolism in the Brain Liver axis in NAFLD (UMBRELLA).

Open Date: 2019-01-01

Close Date: 2020-12-01

Grant: Close

Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease based on Artificial Intelligence.

Open Date: 2018-01-01

Close Date: 2020-01-01

Grant: Close

Esteatohepatitis no alcohólica como enfermedad inflamatoria inmunomediada. Prevalencia y caracterización. Estudio INSTInCT.

Open Date: 2018-01-01

Close Date: 2021-01-01

Grant: Close

Estudio multicéntrico,aleatorizado,controlado y doble ciego de eficacia y seguridad de la tubulización gástrica por vía endoscópica en pacientes con esteatohepatitis no alcohólica.

Open Date: 2018-01-01

Close Date: 2021-01-01

Javier Crespo

Profesor Titular

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Recent Grants

Articles30

Head and neck cancer after liver transplantation in the north of Spain

Prevention of Antipsychotic-Induced Weight Gain: Beyond Metformin

Defining non-invasive criteria for indicating drug therapy in metabolic-associated steatotic liver disease in clinical practice.

Erratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80].

Mexican consensus on the approach to and treatment of acute variceal bleeding.

Supplementary Material for Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data from Nine Countries.

GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus

Overlooked determinants and unequal outcomes: rethinking metabolic dysfunction-associated steatotic liver disease beyond the biomedical model.

Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study.

The Spanish National Strategic Plan for Hepatitis C: A legacy of success.

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study

Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.

Position paper on perioperative management and surgical risk in the patient with cirrhosis.

Towards Eradicating Hepatitis C in Spain: early insights from the Cantabria Cohort Study.

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.

Cohorte Cantabria - A biomedical research tool open to the world.

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

Agentes infecciosos y malabsorción intestinal

Risk of Recurrence of Hepatocarcinoma after Liver Transplantation: Performance of Recurrence Predictive Models in a Cohort of Transplant Patients

The path to successful hepatitis C elimination in Spain

Comparative Study Of The Effectiveness Of Vedolizumab Versus Ustekinumab After Anti-Tnf Failure In Crohn's Disease (Versus-Cd): Data From Eneida Registry.

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.

Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function.

High accuracy of spleen stiffness measurement in diagnosing clinically significant portal hypertension in metabolic‐associated fatty liver disease

Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF).

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key

Collaborators23

Fabien Zoulim

Markus Schlaich

Marcus Vinicius Guimarães de Lacerda

Joost Boeckmans

Emilio Fábrega

Thomas Karlas

Nguan Soon Tan

Hayato Nakagawa

Jinwen Chen

ANGELOS HATZAKIS

Miguel Fidalgo

Quentin M. Anstee

Qiuwei Pan

ANGELA PUENTE

Dr. med. Omar Thaher

Professor Laith Alrubaiy

Julio Pascual

Stefano Romeo

Jose Ignacio Fortea

Jerzy Jaroszewicz

Carmelo Morales-Angulo

Marta Alonso Peña

Ana Peleteiro Vigil

How do I reach out?